Lateral Flow Assays Market to Reach USD 12.52 Billion by 2030
The global lateral flow assays market is projected to grow from USD 8.51 billion in 2025 to USD 12.52 billion by 2030, registering a CAGR of 8.0% during the forecast period. The growth of the market is largely driven by the increasing prevalence of infectious diseases worldwide, the rapid expansion of the geriatric population, and the growing demand for rapid and point-of-care (POC) diagnostic solutions. In addition, the increasing use of home-based lateral flow assay devices and rising awareness regarding early disease detection are contributing to the steady adoption of these testing solutions. However, certain factors, including inconsistent accuracy compared with laboratory-based diagnostic techniques and the reluctance of healthcare providers to transition from conventional diagnostic methods, are restraining market expansion to some extent.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133
Growing Geriatric Population Driving Demand for Rapid Diagnostic Solutions
One of the key factors driving the growth of the lateral flow assays market is the rapid expansion of the global geriatric population. Aging populations are more susceptible to chronic diseases and infectious conditions due to weakened immune systems and age-related physiological changes. These factors increase the demand for accessible, rapid, and reliable diagnostic tools that can assist healthcare providers in early disease detection and management.
According to data published by The Lancet, the global population aged 60 years and above reached 1.1 billion in 2022, accounting for 13.9% of the total global population of 7.9 billion. This demographic group is expected to grow significantly over the coming decades and is projected to reach 2.1 billion by 2050, representing approximately 22% of the global population. The growth of this population segment is anticipated across all major regions worldwide between 2020 and 2050.
With the increasing prevalence of age-related conditions such as cardiovascular disorders, hepatitis, cystic fibrosis, and various forms of cancer, healthcare systems are under pressure to adopt diagnostic technologies that can deliver quick and cost-effective results. Lateral flow assays offer advantages such as rapid turnaround time, ease of use, portability, and minimal training requirements, making them ideal for decentralized testing environments including clinics, community healthcare settings, and home-based care. As governments and healthcare providers increasingly focus on preventive healthcare and early diagnosis, lateral flow assay technologies are expected to play a critical role in supporting the growing diagnostic needs of the aging global population.
Expanding Applications Creating New Growth Opportunities
Over the past two decades, lateral flow assay technologies have evolved significantly, expanding their use far beyond traditional infectious disease diagnostics. While these tests are widely utilized for detecting infectious diseases, cardiac markers, and veterinary pathogens, new applications across several industries are opening additional growth opportunities for market participants.
One of the emerging areas for lateral flow assays is saliva-based diagnostics, which offers a non-invasive testing approach and improves patient comfort and compliance. In addition, the technology is gaining traction in behavioral health testing, where rapid screening tools are required for substance abuse detection and monitoring.
The agriculture sector has also begun leveraging lateral flow assays for genetically modified organism (GMO) detection and crop quality testing, helping ensure compliance with regulatory standards and improving food supply chain transparency. Similarly, the technology is being adopted in environmental monitoring, where it helps detect contaminating enzymes and harmful biological agents in manufacturing plants and industrial environments.
Another growing application area includes food microbiology testing, where lateral flow assays are used to detect harmful pathogens such as E. coli O157, Salmonella, and Listeria. These pathogens pose significant risks to food safety and public health, making rapid testing technologies essential for maintaining quality control across food processing and distribution networks.
Additionally, lateral flow assays are being explored in biodefense and biosecurity applications, including the detection of biological threats such as anthrax. The continued diversification of applications across healthcare, agriculture, environmental monitoring, and food safety is expected to significantly expand the addressable market for lateral flow assay technologies in the coming years.
Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133
Technological Advancements and Market Segmentation Strengthening Adoption
Technological innovations and product diversification are also playing a crucial role in shaping the growth of the lateral flow assays market. Based on product type, the market is segmented into lateral flow readers and kits & reagents, with the kits & reagents segment dominating the market in 2024. The widespread use of kits and reagents for point-of-care testing, increasing prevalence of chronic diseases, and growing demand for home-based testing solutions have contributed to the strong adoption of these products. Their ease of use, rapid results, and cost-effectiveness make them particularly attractive for both clinical and non-clinical applications.
From an application perspective, the market is categorized into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing. Among these segments, clinical testing accounted for the largest market share in 2024, driven by the rising incidence of infectious and chronic diseases worldwide, growing patient awareness of rapid diagnostic solutions, and increasing pressure on healthcare systems to reduce diagnostic costs while improving patient outcomes.
Based on technique, the lateral flow assays market includes competitive assays, sandwich assays, and multiplex detection assays. Among these, sandwich assays dominated the market in 2024, owing to their superior sensitivity and specificity. These assays are widely used for detecting critical analytes such as cardiac markers and hepatitis-related biomarkers, which require accurate and reliable testing methods.
When segmented by sample type, the market includes blood, urine, saliva, and other samples such as nasal swabs, throat swabs, and vaginal fluid. Blood samples accounted for the largest share of the market in 2024, as blood-based testing allows for efficient detection of antibodies and disease biomarkers. Meanwhile, saliva-based testing is gaining attention as a non-invasive diagnostic option for certain conditions.
In terms of end users, the market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and others. The hospitals and clinics segment held the largest share in 2024, supported by technological advancements in point-of-care diagnostics and the increasing demand for rapid disease detection and treatment decision-making.
Regionally, North America currently leads the lateral flow assays market due to its well-established diagnostic infrastructure, high adoption of rapid testing technologies, and ongoing investments in infectious disease monitoring. Europe also represents a significant market, supported by strong screening programs and the increasing use of decentralized diagnostics. Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by rising healthcare expenditures, government-led disease control initiatives, and increasing adoption of home-based diagnostic testing across developing economies.
Key companies operating in the global lateral flow assays market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), Surmodics, Inc. (US), and OraSure Technologies Inc. (US). These companies are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their positions in the rapidly evolving diagnostic testing landscape.
Related Reports-
Point of Care Diagnostics Market
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lateral-flow-assay-market-167205133.html
